Home

Jason Ryan

CIK 1585017 · Executive Chairman · last filed 2026-06-23

Jason Ryan is an Executive Chairman who has filed 67 SEC Form 4 insider transactions across 7 companies since 2014. The most recent filing, for WGS, was dated Jun 23, 2026. Across all open-market trades the lifetime net is −$18.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $10.1M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$10.13M

Companies

7

Total Filings

67

Lifetime Open-Market Net

-$18.54M

Filer Profile

Reported Address
C/O FOUNDATION MEDICINE, INC.
ONE KENDALL SQUARE, SUITE B3501
CAMBRIDGE, MA 02139
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
WGS Director 118,764 $85.27 $10.13M $0 1 2026-06-23
GeneDx Holdings Corp. (WGSWW) Delisted Director 135,473 $0.00 $27 -$8.15M 11 2025-08-27
Singular Genomics Systems, Inc. (OMIC) Delisted Director — $20.01 — $0 3 2024-05-31
SomaLogic, Inc. (SLGCW) Delisted Director — $0.09 — $0 1 2023-06-12
GeneDx Holdings Corp. (SMFRW) Delisted Executive Chairman 263,358 $0.02 $6.3K -$20.4K 6 2023-01-04
Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted See Remarks — $11.19 — $0 2 2020-02-12
Foundation Medicine, Inc. (FMI) Delisted Chief Financial Officer 49,170 — — -$10.37M 38 2018-07-05

Recent Filings

67 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-23 WGS Exer (M) +3,576 $0 EDGAR
2025-08-27 WGS Notice (144) −39,222 -$4.99M EDGAR
2025-08-27 GeneDx Holdings Corp. (WGSWW) Delisted Sell (S) −39,222 -$5.00M EDGAR
2025-06-23 GeneDx Holdings Corp. (WGSWW) Delisted Mixed +12,924 $0 EDGAR
2025-02-25 — Disp (D) — $0
2024-11-21 GeneDx Holdings Corp. (WGSWW) Delisted Mixed −188,356 -$3.32M EDGAR
2024-11-19 WGS Notice (144) −47,000 -$3.29M EDGAR
2024-10-17 GeneDx Holdings Corp. (WGSWW) Delisted Exer (M) +130 $0 EDGAR
2024-06-27 GeneDx Holdings Corp. (WGSWW) Delisted Grant (A) — $0 EDGAR
2024-05-31 Singular Genomics Systems, Inc. (OMIC) Delisted Grant (A) — $0 EDGAR
Showing 1–10 of 67
Page 1 of 7
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.